Acerta Pharma B.V. et al v. Alembic Pharmaceuticals Limited
| Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Merck Sharp & Dohme B.V. |
| Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. |
| 1:2022cv00154 |
| February 2, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 1, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 20 REDACTED VERSION of #16 Order, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Silver, Daniel) |
| Filing 19 REDACTED VERSION of #15 Stipulation, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Silver, Daniel) |
Filing 18
SO ORDERED, re #17 MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein, Claire A. Fundakowski, and Sharon Lin of Winston & Strawn LLP, filed by Alembic Pharmaceuticals Limited. Signed by Judge Richard G. Andrews on 3/31/2022. (nms)
|
| Filing 17 MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein, Claire A. Fundakowski, and Sharon Lin of Winston & Strawn LLP - filed by Alembic Pharmaceuticals Limited. (Gattuso, Dominick) |
|
Filing 16
[SEALED] ORDER Granting #15 Stipulation and Proposed Order Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice. Signed by Judge Richard G. Andrews on 3/28/2022.*This order has been emailed to local counsel. (nms)
|
| Filing 15 [SEALED] STIPULATION and [Proposed] Order Dismissing Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Joyce, Alexandra) |
| Pro Hac Vice Attorney Jovial Wong for Alembic Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (smg) |
| Filing 14 MOTION for Pro Hac Vice Appearance of Attorney Jovial Wong of Winston & Strawn LLP - filed by Alembic Pharmaceuticals Limited. (Gattuso, Dominick) |
|
Filing 13
SO ORDERED Granting #12 Stipulation and Order Dismissing Without Prejudice Defendant Alembic Pharmaceuticals, Inc. and Amending Caption to Reflect Same (*Party Alembic Pharmaceuticals, Inc. terminated). Signed by Judge Richard G. Andrews on 3/3/2022. (nms)
|
| Filing 12 STIPULATION of Dismissal Without Prejudice as to Defendant Alembic Pharmaceuticals, Inc., by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Gattuso, Dominick) Modified on 3/3/2022 (nms). |
| CORRECTING ENTRY: The patent report filed at D.I. 14 has been removed as it was entered in error. (nms) |
|
SO ORDERED, re #14 MOTION for Pro Hac Vice Appearance of Attorney Jovial Wong of Winston & Strawn LLP, filed by Alembic Pharmaceuticals Limited. Signed by Judge Richard G. Andrews on 3/3/2022. (nms)
|
| Pro Hac Vice Attorney Kevin Hoagland-Hanson, Min Kyung Jeon, Stanley E. Fisher, David I. Berl, and Sarahi Uribe for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V., added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(smg) |
| Filing 11 MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon - filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Certifications for David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon)(Joyce, Alexandra) |
|
SO ORDERED, re (12 in 22-cv-164-RGA; 11 in 22-cv-155-RGA; 11 in 22-cv-162-RGA; 11 in 22-cv-163-RGA; 11 in 22-cv-154-RGA) MOTION for Pro Hac Vice Appearance of Attorney David I. Berl, Stanley E. Fisher, Kevin Hoagland-Hanson, Sarahi Uribe, and Min Kyung Jeon, filed by Merck Sharp & Dohme B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, Acerta Pharma B.V.. Signed by Judge Richard G. Andrews on 2/17/2022. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA(nms)
|
| Filing 10 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to April 11, 2022 - filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Gattuso, Dominick) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:22-cv-00154-RGA, 1:22-cv-00155-RGA, 1:22-cv-00162-RGA, 1:22-cv-00163-RGA, 1:22-cv-00164-RGA (rjb) |
|
SO ORDERED, re #10 STIPULATION and Order to Extend Time to answer, move or otherwise respond to the Complaint (*Reset Answer Deadlines: Alembic Pharmaceuticals Limited answer due 4/11/2022; Alembic Pharmaceuticals, Inc. answer due 4/11/2022). Signed by Judge Richard G. Andrews on 2/9/2022. (nms)
|
| Filing 9 SUMMONS Returned Executed by AstraZeneca AB, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. Alembic Pharmaceuticals, Inc. served on 2/3/2022, answer due 2/24/2022. (Joyce, Alexandra) |
| Filing 8 DECLARATION of Service of Alembic Pharmaceuticals Limited, by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 2/10/2022 (nms). |
| Filing 7 Summons Issued with Magistrate Consent Notice attached as to Alembic Pharmaceuticals Limited on 2/2/2022; Alembic Pharmaceuticals, Inc. on 2/2/2022. (Attachments: #1 Summons Issued)(mal) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited filed by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (mal) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme B.V. filed by Merck Sharp & Dohme B.V.. (mal) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,758,524 ;10,239,883 ;9,796,721 ;10,167,291 ;10,272,083. (mal) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 12/28/2021. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: No earlier than 4/30/2025. (mal) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Filing 1 COMPLAINT filed against Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3794344.) - filed by AstraZeneca AB, Acerta Pharma B.V., AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Merck Sharp & Dohme B.V.. (Attachments: #1 Exhibit A-E, #2 Civil Cover Sheet)(mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
